QUOTE AND NEWS
Globe Newswire  Oct 29  Comment 
DALLAS, Oct. 29, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Metabasis Therapeutics (Nasdaq:MBRX). The report includes financial and investment analysis, analyst consensus, and pertinent industry information
FierceBiotech  Oct 27  Comment 
Less than two months after its CEO announced plans to jump ship, Ligand Pharmaceuticals announced a deal to buy the struggling La Jolla, CA-based Metabasis (MBRX) for only $3.2 million in cash--less net liabilities--and contingency value rights...
FierceBiotech  Sep 2  Comment 
The CEO of Metabasis Therapeutics, Mark Erion, is leaving his post to join Merck as vice president and head of its worldwide franchise for obesity and diabetes. Metabasis has been struggling to garner enough cash to keep its doors open....
StreetInsider.com  Jun 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Metabasis+%28MBRX%29+To+Receive+%246M+Fee+From+Merck%2C+But+Still+Warns+About+Its+Future/4722746.html for the full story.
StreetInsider.com  Jun 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/FDA/Metabasis+Therapeutics+%28MBRX%29+Receives+%242M+Payment+From+Roche/4714074.html for the full story.




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Metabasis Therapeutics, Inc. is a biopharmaceutical company that engages in the discovery and development of drugs for chronic diseases involving pathways in the liver. The company provides products primarily for metabolic diseases, such as diabetes, hyperlipidemia, and liver diseases, including hepatitis and liver cancer. The company's pipeline candidates include MB07133 (for the treatment of primary liver cancer), MB07803 (for the treatment of type-II diabetes), and MB07811 (for the management of hyperlipidemia), all of which are in early-to-mid stages of clinical development. Metabasis received disappointing news in July 2007 related to the clinical development of two mid-stage candidates - CS-917 (for the treatment of type-II diabetes) and pradefovir (for the treatment of hepatitis B). While CS-917 failed to achieve the primary endpoint in a phase IIb trial, results from toxicology studies for pradefovir showed a higher dose-related incidence of cancer. The pradefovir news resulted in the termination of the company's development and commercialization agreement with Schering-Plough. As far as CS-917 is concerned, Metabasis announced that it will not continue with the development of the candidate.

Metabasis Therapeutics has strategic alliances with several larger pharmaceutical companies, including Valeant Pharmaceuticals, Daiichi Sankyo Co., Ltd., and Merck & Co. These collaborations helped Metabasis generate $4.4 million in revenues in 2006. Metabasis Therapeutics, Inc. is based in La Jolla, California.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki